RG

Regenicin IncOOTC RGIN Stock Report

Last reporting period 31 Mar, 2023

Updated 11 Nov, 2024

Last price

Market cap $B

0

Micro

Exchange

OOTC - OTC

RGIN Stock Analysis

RG

Uncovered

Regenicin Inc is uncovered by Eyestock quantitative analysis.

Market cap $B

0

Dividend yield

Shares outstanding

153.48 B

Regenicin, Inc. is a biotechnology company that is focused on the development of regenerative cell therapies to restore the health of damaged tissues and organs. The Company is focused on developing and commercializing a lifesaving technology through the introduction of tissue-engineered skin substitutes to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a range of plastic surgery procedures. Its product, NovaDerm, is a multi-layered tissue-engineered skin prepared by utilizing autologous skin cells. NovaDerm is a graftable cultured epithelium skin substitute containing both epidermal and dermal components. It is focused on developing its product, TempaDerm. TempaDerm cells develop banks of cryo-preserved (frozen) cells and cultured skin substitutes to provide a continuous supply of non-allogenic skin substitutes to treat smaller wound areas in patients, such as ulcers. Its application is used for the treatment of chronic skin wounds.

View Section: Eyestock Rating